Cobra says agrees to manufacture Pharmexa's bone disorder vaccine candidate |
|
|
|
Published
:
Thu, 01 Feb 2007 10:47 |
LONDON (AFX) - Biopharmaceuticals manufacturer Cobra Bio-Manufacturing PLC said it signed an agreement with Pharmexa for the manufacture of the protein vaccine PX107 for use in Phase I clinical trials for bone disorders.Cobra said it will manufacture the therapeutic vaccine, PX107, which uses Pharmexa's proprietary active immunotherapy technology, AutoVac.The company said the vaccine is in pre-clinical development to treat osteoporosis, rheumatoid arthritis and bone metastasis with pathological bone destruction.newsdesk@afxnews.comrda/ambCOPYRIGHTCopyright AFX News Limited 2006. All rights reserved.The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.AFX News and AFX Financial News Logo are registered trademarks of AFX News Limited
|
|
|
|